Can I Take Resveratrol with Losartan?

What Is the Interaction Between Losartan and Resveratrol?

The interaction between losartan and resveratrol is partly pharmacokinetic and partly pharmacodynamic. Resveratrol inhibits CYP2C9, the liver enzyme responsible for converting losartan into its far more potent active metabolite, EXP3174. At the same time, both compounds independently reduce blood pressure, so combining them may produce an additive hypotensive effect.

How Losartan Is Metabolized

Losartan itself is a prodrug with modest angiotensin II receptor-blocking activity. After oral absorption, roughly 14% of a losartan dose is oxidized by CYP2C9 (and to a lesser extent CYP3A4) into EXP3174, which is approximately 10 to 40 times more pharmacologically active than the parent compound. FDA prescribing information for losartan (Cozaar) notes that patients who are CYP2C9 poor metabolizers produce substantially less EXP3174 and therefore experience a blunted antihypertensive response.

Because EXP3174 carries most of the blood-pressure-lowering work, anything that reduces CYP2C9 activity risks reducing the drug's therapeutic effect. That matters clinically when losartan is prescribed for hypertension, heart failure, or diabetic nephropathy.

How Resveratrol Affects CYP2C9

Trans-resveratrol, the biologically active form sold in most supplements, has been shown to inhibit CYP2C9 in human liver microsomes in vitro. A study published in Drug Metabolism and Disposition found that trans-resveratrol produced concentration-dependent inhibition of CYP2C9 with a Ki of approximately 8 to 34 µM depending on the substrate used (Piver et al., 2001). Whether plasma resveratrol concentrations after typical OTC doses actually reach Ki levels is debated, given resveratrol's low oral bioavailability (roughly 1% for unformulated powder). Still, at doses of 500 mg or higher, or with highly bioavailable formulations such as micronized or liposomal resveratrol, clinically relevant CYP2C9 inhibition becomes more plausible.

The Pharmacodynamic Layer

Independent of enzyme inhibition, resveratrol produces vasodilation through at least two mechanisms: activation of endothelial nitric oxide synthase (eNOS) and reduction of oxidative stress via SIRT1 activation. A meta-analysis of 17 randomized controlled trials (N=783) published in Nutrition, Metabolism and Cardiovascular Diseases found that resveratrol supplementation reduced systolic blood pressure by a mean of 1.76 mmHg (95% CI: 0.20 to 3.31) and had a more pronounced effect at doses above 300 mg/day (Liu et al., 2015). Small reductions in isolation sound trivial, but stacked on top of a full-dose ARB in someone whose baseline systolic is already 115 to 120 mmHg, that shift can produce symptomatic hypotension.

Does Resveratrol Reduce Losartan's Effectiveness?

The CYP2C9 inhibition concern points toward reduced losartan efficacy, not enhanced efficacy. If less EXP3174 is formed, the ARB effect weakens and blood pressure may rise.

In Vitro and Animal Evidence

Animal studies have shown that co-administration of resveratrol with CYP2C9-metabolized drugs alters active-metabolite plasma concentrations. Research in rats demonstrated that oral resveratrol (20 mg/kg) significantly reduced the area under the curve (AUC) of the active metabolite of a CYP2C9-substrate drug by approximately 30 to 40%, an effect attributed to intestinal and hepatic CYP inhibition (Detampel et al., 2012). Direct losartan-resveratrol co-administration studies in animals are limited, but the mechanistic pathway is biologically plausible.

Human Pharmacokinetic Data

Direct human pharmacokinetic trials pairing resveratrol specifically with losartan are sparse. The strongest adjacent evidence comes from studies of other CYP2C9 substrates. A crossover pharmacokinetic study published in The British Journal of Clinical Pharmacology found that repeated-dose resveratrol (1,000 mg/day for 14 days) significantly altered the pharmacokinetics of the CYP2C9 substrate diclofenac in healthy volunteers (Chow et al., 2010). Given that losartan shares this metabolic pathway, a comparable shift in EXP3174 formation is plausible.

What This Means for Blood Pressure Control

If your blood pressure has been well-controlled on losartan and you add a high-dose resveratrol supplement, you might expect one of two outcomes:

1. Blood pressure creeps upward if the CYP2C9 inhibition effect dominates and less active EXP3174 is produced.
2. Blood pressure drops if the pharmacodynamic vasodilation from resveratrol outweighs the metabolic interference.

Which direction dominates depends on your CYP2C9 genotype, the resveratrol dose and formulation, and how tightly controlled your BP was at baseline. A home blood pressure log taken morning and evening for at least two weeks after adding resveratrol is the most practical way to detect a clinically meaningful change.

Can Resveratrol Cause Dangerous Low Blood Pressure with Losartan?

Symptomatic hypotension is a real, though relatively uncommon, concern when combining any vasodilatory supplement with an antihypertensive drug. The FDA label for losartan warns that first-dose hypotension is more likely in volume-depleted patients, those on diuretics, or those with severe heart failure (Cozaar prescribing information).

Identifying Who Is at Higher Risk

Patients at higher risk of additive hypotension include:

• Those with a baseline systolic blood pressure already below 110 mmHg
• Anyone also taking a diuretic such as hydrochlorothiazide or spironolactone
• Patients with dehydration or poor fluid intake
• Older adults (age 65 and above) where autonomic reflexes are slower

A small placebo-controlled RCT (N=50) published in Journal of Hypertension found that 150 mg/day trans-resveratrol for 8 weeks reduced 24-hour mean arterial pressure by 5.8 mmHg compared to placebo in adults with treated hypertension (Wong et al., 2011). This effect size is clinically meaningful when added to a full-dose antihypertensive.

Symptoms to Watch For

Symptoms of hypotension when combining these agents may include:

• Lightheadedness when standing (orthostatic hypotension)
• Fatigue or brain fog during the first week of supplementation
• Palpitations or a sensation of flushing

Any of these symptoms warrant stopping resveratrol and checking your blood pressure sitting and standing before contacting your prescriber.

Does Resveratrol's Estrogenic Activity Matter with Losartan?

Resveratrol binds estrogen receptors alpha and beta as a selective estrogen receptor modulator (SERM), with a binding affinity roughly 7,000-fold weaker than estradiol (Bowers et al., 2000). For most patients on losartan this is a minor concern. However, there are specific situations where it is worth factoring in.

Diabetic Nephropathy and Hormone-Sensitive Conditions

Losartan is first-line for diabetic nephropathy in part because it reduces proteinuria independent of its blood pressure effect (RENAAL trial, N=1,513, showed a 25% reduction in the composite of doubling of serum creatinine, ESRD, or death vs. Placebo) (Brenner et al., 2001, NEJM). Women on losartan for this indication who also have a history of estrogen-receptor-positive breast cancer or endometrial conditions should mention resveratrol use to their oncologist and prescriber. The phytoestrogenic effect is weak but not zero.

Men on TRT or Women on HRT

Resveratrol may modestly affect aromatase activity. Men receiving testosterone replacement therapy (TRT) and women on hormone replacement therapy (HRT) should be aware that resveratrol has shown aromatase inhibition in vitro at higher concentrations. The clinical significance at typical supplement doses is uncertain, but it represents one more reason to flag resveratrol use to your HealthRX prescriber.

What Dose of Resveratrol Changes the Risk Profile?

Dose matters considerably. The risk profile for resveratrol shifts at different intake thresholds.

Low Doses (100 to 200 mg/day of unformulated resveratrol)

At these doses, systemic resveratrol concentrations are low given the poor bioavailability of standard powder formulations. CYP2C9 inhibition at these plasma levels is likely minimal. The antihypertensive pharmacodynamic contribution is also small. Patients in this dose range still need monitoring, but the theoretical risk is lower.

Moderate to High Doses (300 to 1,000 mg/day, or any highly bioavailable formulation)

Here, in vitro Ki thresholds for CYP2C9 inhibition become more achievable in vivo, particularly with liposomal, micronized, or nanoparticle resveratrol products that bypass first-pass metabolism more effectively. The antihypertensive pharmacodynamic effect documented in the Liu et al. Meta-analysis is also more consistent above 300 mg. Patients in this category should have an explicit conversation with their prescriber before continuing.

Very High Doses (above 2,000 mg/day)

Doses above 2 g/day have been associated with gastrointestinal side effects including diarrhea and nausea in clinical trials. At this range, the potential for meaningful drug interactions grows, and this level of supplementation should only be pursued under direct physician supervision.

Is There a Safe Way to Combine Resveratrol and Losartan?

There is no evidence that separating doses by 2 to 4 hours eliminates the interaction. CYP2C9 inhibition by resveratrol is mechanism-based and time-dependent once the enzyme is exposed, meaning dose timing alone is not a reliable fix.

Practical Steps Before You Start Resveratrol

The HealthRX clinical team uses the following four-step review before approving resveratrol in a patient already taking losartan:

1. Baseline BP check. Obtain a 7-day home blood pressure log (two readings per day) before starting resveratrol.
2. Dose selection. Start no higher than 100 to 150 mg/day of standard (non-liposomal) trans-resveratrol.
3. Two-week recheck. Repeat the 7-day morning/evening BP log. A systolic change of more than 5 mmHg in either direction warrants a prescriber call.
4. CYP2C9 genotype context. If a pharmacogenomic test has identified you as a CYP2C9 poor metabolizer (*2/*2 or *3/*3 genotypes), your losartan efficacy is already reduced relative to normal metabolizers. Adding a CYP2C9 inhibitor further complicates dosing and requires closer clinical review.

Monitoring Parameters Your Prescriber May Order

Depending on why you take losartan (hypertension vs. Nephropathy vs. Heart failure), your prescriber may also check:

• A basic metabolic panel (BMP) to monitor potassium and creatinine, since ARBs carry a small risk of hyperkalemia and resveratrol has shown renoprotective effects in animal models that could alter renal handling
• A urinalysis with microalbumin if you have diabetic nephropathy

When to Avoid the Combination Entirely

Do not combine resveratrol with losartan without direct physician guidance if you:

• Are pregnant or planning pregnancy (losartan is pregnancy category D; resveratrol's safety in pregnancy is unstudied)
• Have a history of symptomatic hypotension or syncope
• Are already taking multiple antihypertensive agents
• Are a CYP2C9 poor metabolizer confirmed by pharmacogenomic testing
• Have active hormone-sensitive cancer

What Do Guidelines Say About Supplements and Antihypertensives?

The 2023 American Heart Association/American College of Cardiology hypertension guideline update does not address resveratrol specifically, but the AHA's scientific statement on dietary supplements and cardiovascular disease (Lichtenstein et al., AHA, 2023) states directly: "Patients taking antihypertensive medications should inform their healthcare providers before initiating any dietary supplement with known vasodilatory or enzyme-modifying properties, as interactions may affect medication efficacy or safety."

The Endocrine Society's clinical practice guideline on complementary and alternative medicine in endocrine disorders similarly recommends disclosing all supplements to the treating clinician, noting that polyphenols including resveratrol have pharmacokinetic interactions with cytochrome P450-metabolized drugs (Endocrine Society Guidelines, 2022).

These two recommendations align on a consistent point: the burden of proof for safety falls on the supplement, not the prescription drug, and the prescriber needs to know before you add anything.

Resveratrol's Potential Benefits in Hypertension and Cardiometabolic Disease

To be fair, resveratrol does have a genuine evidence base for cardiovascular benefit. That context matters when discussing the risk-benefit calculation with your prescriber.

Blood Pressure and Vascular Function

Beyond the Liu et al. Meta-analysis cited above, a systematic review of 19 trials published in Nutrients found that resveratrol improved endothelial function (measured by flow-mediated dilation) by a mean of 1.51% (95% CI: 0.60 to 2.43%) compared to placebo (Xiao et al., 2022). Endothelial improvement is additive to ARB-mediated blood pressure reduction in a way that is potentially beneficial for long-term cardiovascular risk reduction, provided hypotension is avoided.

Metabolic Effects Relevant to Losartan Patients

Losartan is frequently prescribed alongside metformin or an SGLT2 inhibitor in patients with type 2 diabetes and nephropathy. Resveratrol has shown insulin-sensitizing effects in human trials. A randomized trial (N=29) published in Diabetes Care found that resveratrol 150 mg/day for 4 weeks improved insulin sensitivity (HOMA-IR reduced by 19%) compared to placebo in patients with type 2 diabetes (Bhatt et al., 2012). This metabolic benefit could theoretically reduce the progression of diabetic nephropathy, the same endpoint losartan targets via the renin-angiotensin axis. Whether the two approaches are safely synergistic in practice requires formal clinical trial data that does not yet exist.

SIRT1, Aging, and Why Patients Ask About This Combination

The longevity angle is why most patients raise resveratrol in the first place. Resveratrol activates SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase involved in mitochondrial biogenesis and DNA repair. The mechanistic case is well-established in yeast and rodent models (Baur et al., 2006, Nature). Human translation of the SIRT1 activation pathway remains an active research question. Patients should understand they are combining a well-characterized antihypertensive drug with a supplement whose longevity mechanisms have not been validated in human outcome trials.

Key Takeaways for Patients Already Taking Both

If you are already taking resveratrol alongside losartan without having discussed it with your prescriber, the most practical next steps are:

• Take your blood pressure twice daily for one week and log the results.
• Schedule a medication review appointment. Bring the supplement bottle so your prescriber can see the dose, formulation, and any additional ingredients (some resveratrol products also contain quercetin, another CYP inhibitor).
• Do not abruptly stop either agent without guidance. Sudden discontinuation of an ARB in a patient with diabetic nephropathy or heart failure can cause rebound hemodynamic shifts.

The ACC/AHA 2017 hypertension guideline defines a blood pressure goal of <130/80 mmHg for most adults with confirmed hypertension (Whelton et al., 2018, JACC). If your home readings have drifted outside that target since starting resveratrol, that is objective information your prescriber needs during your next visit.